PDR Clinical Trial
Official title:
A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Primary objective of this trial will be to evaluate the safety and efficacy of intravitreal
injections of Macugen (pegaptanib sodium) when given at least 7-14 days prior to vitrectomy
in subjects with tractional retinal detachment (with or withoutmacular involvement)
secondary to proliferative diabetic retinopathy.
Secondary objective is to evaluate regression of neovascularization and progression of
macular traction utilizing OCT and fundus photographs.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03113006 -
The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study (TREAT)
|
N/A |